APA (7th ed.) Citation

Brodowicz, T., Lang, I., Kahan, Z., Greil, R., Beslija, S., Stemmer, S. M., . . . Zielinski, C. (2014). Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. British Journal of Cancer, 111(11), 2051. https://doi.org/10.1038/bjc.2014.504

Chicago Style (17th ed.) Citation

Brodowicz, T., et al. "Selecting First-line Bevacizumab-containing Therapy for Advanced Breast Cancer: TURANDOT Risk Factor Analyses." British Journal of Cancer 111, no. 11 (2014): 2051. https://doi.org/10.1038/bjc.2014.504.

MLA (9th ed.) Citation

Brodowicz, T., et al. "Selecting First-line Bevacizumab-containing Therapy for Advanced Breast Cancer: TURANDOT Risk Factor Analyses." British Journal of Cancer, vol. 111, no. 11, 2014, p. 2051, https://doi.org/10.1038/bjc.2014.504.